Switch On Discovery. Switch Off Disease. At Mirimus, we harness the precision of RNA interference (RNAi) to silence disease genes and unlock new biological insights. With decades of innovation, our expert team delivers customizable RNAi solutions, from siRNA and shRNA design to in vivo validation, empowering researchers to control gene expression, validate targets, and accelerate breakthroughs across oncology, neurology, and genetic disorders.
With years of experience in RNAi research and drug development, Mirimus is your trusted partner for gene silencing solutions. Our expert team is committed to delivering personalized, high-quality services that support your research and therapeutic development. We prioritize:
We use cutting-edge tools and methodologies to design RNAi molecules that achieve precise gene knockdown with high specificity.
Our custom delivery systems ensure that RNAi molecules are efficiently transferred into target cells, maximizing therapeutic outcomes.
We stay at the forefront of RNAi technologies, constantly advancing our methods to offer the most innovative and effective solutions.
Our team specializes in designing siRNAs and shRNAs that specifically target your gene of interest, providing robust gene knockdown with minimal off-target effects. Using sophisticated bioinformatics tools and extensive knowledge of RNA structure, we optimize these RNA molecules to ensure maximum silencing efficiency while maintaining high levels of specificity.
In silico design to identify optimal siRNA and shRNA sequences
Validation and testing for gene knockdown efficiency in vitro
Custom synthesis and purification of siRNAs and shRNAs to your specifications
Mirimus offers advanced artificial miRNA design services, enabling researchers to leverage natural miRNA pathways for precise gene expression modulation. Artificial miRNAs can be designed to target multiple genes simultaneously, providing a more refined approach to gene regulation. Our artificial miRNAs are engineered to function similarly to endogenous miRNAs, making them ideal tools for exploring complex gene networks, conducting high-throughput studies, or developing therapeutic candidates.
Custom miRNA sequences for specific gene targets
Dual targeting capabilities for enhanced gene silencing
miRNA-mimic constructs for therapeutic and research applications
Effective RNAi therapy relies not only on the design of RNAi molecules but also on efficient delivery systems. At Mirimus, we provide cutting-edge solutions to ensure the reliable transfer of RNAi therapeutics into target cells.
Lipid Nanoparticle (LNP) Formulations: Our custom LNP formulations encapsulate RNAi molecules, protecting them from degradation and enabling safe and effective delivery into cells. LNPs have proven to be a key vehicle for delivering siRNAs in vivo, with optimal biodistribution and minimal toxicity.
Viral Vector-Based Delivery Systems: For stable, long-term gene silencing, we offer viral vector systems (such as lentiviral or adenoviral vectors) to deliver RNAi sequences into cells. This approach is ideal for sustained RNAi expression and can be used for both in vitro studies and in vivo models.
RNAi is a powerful tool for validating gene targets and exploring their role in disease pathways. Our RNAi therapeutics platform can be used to investigate gene function in preclinical models, providing valuable insights into gene-disease relationships and advancing the development of novel therapies. We work closely with you to design experiments that validate key targets and accelerate the discovery of RNAi-based therapeutics.
High-throughput screening for gene function analysis
Preclinical validation of RNAi therapeutics in relevant disease models
Assistance in transitioning RNAi candidates into clinical development
Demonstration of reliable superior technology (Watanbe et al., 2016, RNA Biology)
An optimized microRNAbackbone for effective single-copy RNAi (Fellmann et al., 2013, Cell Reports)
Engineered microRNA scaffolds for potent gene silencing in vivo (Militello et al., 2025, Scientific Reports)
Engineered microRNA scaffolds for potent gene silencing in vivo (Militello et al., 2025, Scientific Reports)
Endogenous spacing enables co-processing of microRNAs and efficient combinatorial RNAi (Amen et al., 2022, Cell Reports Methods)
ACKR4 in Tumor Cells Regulates Dendritic Cell Migration to Tumor-Draining Lymph Nodes and T-Cell Priming (Wangmo et al., 2021, Cancers)
Prediction of potent shRNAs with a sequential classification algorithm (Pelossof et al., 2017, Nature Biotechonolgy)
RNAi and CRISPR/Cas9 Based In Vivo Models for Drug Discovery (Premsrirut et al., 2017, Blood)
Nephrin Preserves Podocyte Viability and Glomerular Structure and Function in Adult Kidneys (Li et al., 2015, J Am Soc Nephrol)
Cohesin loss alters adult hematopoietic stem cell homeostasis, leading to myeloproliferative neoplasms (Mullenders et al., 2015, J Exp Med)
PTEN action in leukaemia dictated by the tissue microenvironment (Miething et al., 2014, Nature)
In vivo RNA interference models of inducible and reversible Sirt1 knockdown in kidney cells (Chuang et al., 2014, Am J Pathol)
Translation initiation factor eIF4F modifies the dexamethasone response in multiple myeloma (Robert et al., 2014, Proc Natl Acad Sci USA)
Creating transgenic shRNA mice by recombinase-mediated cassette exchange (Premsrirut et al., 2013, Cold Spring Harb Protoc)
Whether you’re conducting basic research, validating therapeutic targets, or developing RNAi-based therapies, our team is committed to supporting your project at every stage. Discover the potential of RNAi therapeutics with Mirimus and drive your research forward with confidence.
Contact Us
.png)
.png)
